Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib plus ofatumumab in previously treated chronic lymphocytic leukemia
2012-001236-65Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Idelalisib + ofatumumab with Ofatumumab control (2 arms). Primary endpoint: Progression-free survival. Started Nov 2012; status: completed.
02
Drugs
idelalisibofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2012-001236-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001236-65.